PolyNovo Limited

ASX PNV.AX

PolyNovo Limited Shareholders' Equity for the year ending June 30, 2024: USD 48.09 M

PolyNovo Limited Shareholders' Equity is USD 48.09 M for the year ending June 30, 2024, a 10.52% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

PolyNovo Limited Shareholders' Equity for the year ending June 30, 2023 was USD 43.51 M, a 255.91% change year over year.
PolyNovo Limited Shareholders' Equity for the year ending June 30, 2022 was USD 12.23 M, a -27.05% change year over year.
PolyNovo Limited Shareholders' Equity for the year ending June 30, 2021 was USD 16.76 M, a 1.96% change year over year.
PolyNovo Limited Shareholders' Equity for the year ending June 30, 2020 was USD 16.44 M, a -10.31% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

ASX: PNV.AX

PolyNovo Limited

CEO	Mr. Swami Raote BPHARM, M.B.A.
IPO Date	Nov. 30, 1998
Location	Australia
Headquarters	320 Lorimer Street
Employees	254
Sector	Healthcare
Industries Biotechnology 3D Printing Chemicals & Advanced Materials Clinical Trials Medical Instruments Personal Care Pharmaceuticals Plastics

Description

PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

Key trends

Past 5 years